Harnessing the Potential of Adenovirus Vectored Vaccines by Holst, Peter Johannes et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books






Harnessing the Potential of  
Adenovirus Vectored Vaccines 
Peter Johannes Holst,  
Jan Pravsgaard Christensen and Allan Randrup Thomsen 
Department of International Health, Immunology and Microbiology,  
University of Copenhagen, Copenhagen,  
Denmark 
1. Introduction 
A range of infectious diseases and cancers are in theory preventable or treatable by 
vaccination, but have remained outside the reach of traditional vaccination.  This may be 
because of special problems regarding the selection of appropriate target antigens or certain 
requirements regarding the quality of the vaccine induced response. In this context, the use of 
recombinant virus vectored vaccines may be a promising future concept that combines 
important features of live attenuated vaccines with greater safety and the ability to target any 
imaginable antigen. Among the virus vectors investigated for vaccine purposes, adenovirus 
vectors have received considerable attention and today stand among the most potent tools 
available for induction of antibody and CD8+ T cell responses in mice, primates and humans 
(Barefoot et al., 2008; Bett et al., 2010; Shiver et al., 2002). Adenovirus vectored vaccines has, 
however, also been implicated in one of the most spectacular HIV vaccine failures (Buchbinder 
et al., 2008), and some papers describe either undesirable attributes of the adenovirus induced 
T cell response or properties of vector specific responses, which may increase mucosal HIV 
transmission (Benlahrech et al., 2009; Perreau et al., 2008). The current review will attempt to 
describe the key features of adenovirus vectored vaccine induced immune responses, the 
mechanisms underlying induction of different response qualities,  how the adenovirus vectors 
compare with other vaccination tools in the immunological arsenal, and how adenovirus 
vectors can be combined in heterologous vaccination regimens. A final section will be 
dedicated to potential future clinical application of adenovirus vectored vaccines.  
2. Immune responses against adenovirus vectored vaccines - the issue of 
magnitude and functionality 
Although scientific progress had been made using replication incompetent adenovirus vectors 
for vaccination since the late 1980’s (Alkhatib & Briedis, 1988) (see figure 1 for a description of 
the principal immunological differences between replication competent and replication 
incompetent adenovirus vectors), the interest in this vector system exploded with the 
demonstration of antiviral efficacy against simian human immunodeficiency virus (SHIV) of a 
vaccine encoding SIV gag delivered by a human serotype 5 adenovirus vector in non-human 
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primates (NHPs)(Shiver et al., 2002). The failure of modified vaccinia Ankara (MVA) or DNA 
vectors to achieve similar results only served to underscore the potency of the adenoviral vector 
system. However, several reports both preceding and in particularly following the spectacular 
failure of the MERCK STEP trial have highlighted that adenoviral vectored vaccines may 
induces a substantial, yet functionally impaired T cell response (Tatsis et al., 2007a), that in 
many cases nevertheless provide highly significant protection (Yang et al., 2006). In that context 
it is pertinent to note, that adenoviral vaccination seems to induce T cells with a phenotype 
more resembling that associated with a chronic infection than with a resolved acute and self-
limiting infection. Importantly, although the kinetics and magnitude of the reported adenovirus 
induced CD8+ T cell responses vary considerably depending on the encoded antigen as well as 
the route and dose of immunization, the responses are unusually stable over time. Thus, 
memory T cell frequencies frequently stabilizes above 30% of the peak response, which contrast 
with the 5-10% usually found to be associated with acutely resolved infections (Abbink et al., 
2007; Holst et al., 2007; Holst et al., 2010b; Tatsis et al., 2007a) (See figure 2 for a cartoon of the 
different immune response patterns and their associated phenotypic properties).  
 
 
Fig. 1. The principal differences between replication competent and replication incompetent 
viral vectors with regard to source of antigens. Infection with a live replication competent 
vaccine vector (left side) or a replication incompetent vector (right side) differ markedly in the 
ability to present recombinant vaccine antigen. The replication competent vector has less 
cloning capacity (hence the small red fragment symbolizing recombinant antigen) and 
infection of a host cell results in many viral transcripts being produced, including those not 
containing the recombinant insert. On the positive side, the inoculum will be amplified 
(symbolized by the appearance of virus progeny), and present an ongoing infectious signature 
to the innate immune system. Replication incompetent vectors do not become amplified, but 
transcripts containing the recombinant insert dominate the transcription profile of the 
transduced cell. Other popular virus vectors such as vaccinia virus resemble replication 
competent adenovirus in the way in which they present antigen, whereas replication deficient 
variants, such as modified vaccinia Ankara (MVA), more resemble replication incompetent 
vectors (although with more non-recombinant gene expression)  
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Fig. 2. The principal time-course of antigen elimination and CD8+ T cell response after 
a self-limiting acute infection and an adenoviral vaccination. Infection with an acute 
viral infection (green lines)) takes days to reach maximal antigen presentation (dashed 
green line) as viral replication is needed to amplify the inoculum. There is rapid and 
nearly complete elimination of the virus after the peak by the induced CD8+ T cell 
response (full green line) the time-course of which mimics the antigen curve with a few 
days delay. Vaccination with a replication incompetent adenoviral vector (red lines) is 
representing a bolus injection and the peak of antigen expression (dashed red line) is 
reached shortly after virus inoculation. Subsequently antigen presentation gradually 
declines over a protracted time-period. T cell expansion is delayed (full red line) and 
slowly reaches a peak as the majority of the antigen has been eliminated. The response 
then slowly declines, but is maintained at a high level relative to the peak response. The 
relative differences in the resulting memory T cell phenotype is inserted between the lines 
with color coding identifying the two populations.   
2.1 Tissue transduction properties  
The key to untangle these conflicting reports regarding the immunological properties of 
adenovirus vectors may lie in a better understanding of the mechanisms underlying the 
remarkable immunogenicity of adenoviral vectors and its relationship to route, dose and 
antigen presentation. To aid in this understanding we will first consider the unusual 
features of the adenoviral gene delivery system. Adenoviral vectors are not unique in 
their ability to target relevant populations of antigen presenting cells (Lindsay et al., 
2010), but uniquely among all vaccine delivery technologies, adenoviral vectors have also 
received serious attention as vehicles of correctional or experimental gene therapy. Thus, 
adenoviral vectors can be used to transduce a large number of cell types, and intravenous 
or intramuscular application can lead to a situation where most liver cells or cells of the 
infected muscle are expressing vast amount of the transgene (Antinozzi et al., 1999; 
Jimenez-Chillaron et al., 1999; Okuyama et al., 1998). Thus, with the ability to transduce 
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perfectly equipped to induce combined direct and cross-presentation of antigen to CD8+ 
T cells. In agreement with this notion, ubiquitous, keratinocyte specific and alveolar 
epithelial cell specific promoters have been used to induce CD8+ T cell responses towards 
the encoded antigen, and remarkably, no differences in the response level have been 
observed provided the administration route targeted cells with the relevant promoter 
activity (Prasad et al., 2001). Paradoxically, adenoviruses are extremely potent inducers of 
CD8+ T cells directed against the inserted transgene, yet induce levels of CD4+ T cell 
activation similar to that of naked DNA vaccines, which are much less efficient in tissue 
transduction (Wu et al., 2005). This is surprising because the ability to cross-prime CD8+ T 
cells implies that substantial amount of antigen are being released from dying cells, and 
this antigen would normally be expected to represent a good sources of peptides for MHC 
class II restricted presentation to CD4+ T cells. The reasons for this limited ability to 
induce CD4+ T cell responses are currently not understood.  Unfortunately the study 
employing cell type specific promoters for antigen expression did not contain any data 
relating to the immunological potency, the kinetics of the response or the phenotype of 
the CD8+ T cells induced. This means, that while it is likely that both direct and cross-
presentation contribute in the induction of the response, it has until recently been  unclear 
what is the relative contribution of each type of antigen presentation pathway, how this 
contribution may differ between different antigens and how this may affect the 
phenotypes of the responding T cells. Recent work by our group (Holst et al., 2010b) and 
the group of Jonathan L. Bramson (Bassett et al., 2011; Finn et al., 2009; Yang et al., 2006) 
has now begun to address this issue in greater detail.  
2.2 The issue of dose  
Initially we discovered that increasing the dose of s.c. administered adenovirus from 109 to 
1010 or 1011 particles, caused most of the increased inoculum to enter the systemic circulation 
and transduce the cells of the liver and spleen at levels comparable to those found after an 
i.v. administration (Holst et al., 2010b) (see figure 3). Intravenous administration was found 
to induce a slow response and require more vector for initiating a transgene specific 
response (1010 particles i.v., while 109 or less sufficed for s.c. administration). This is 
consistent with the notion that a key to a potent immune response is efficient priming in the 
local environment of the lymph nodes draining the injection site, and we were able to 
substantiate this suggestion by observing markedly impaired responses in L-selectin 
deficient mice after peripheral immunization using a moderate dose of adenovirus vectored 
vaccine (Holst PJ, Thomsen AR and Christensen JP, unpublished) (see figure 4A). However, 
after a considerable delay, i.v. administered adenovirus did induce a transgene specific 
CD8+ T cell response, which eventually surpassed the response following s.c. immunization 
in terms of cell numbers generated.  For both routes of virus administration we found a 
positive correlation between the amount of vector reaching the systemic circulation and the 
magnitude of the response, whereas an inverse correlation was noted with regard to the 
quality of the response as measured by cytokine producing competence.  These observations 
led us to suggest that dissemination of the vector was responsible for the apparent reduction 
in T cell quality in i.v. immunized mice. Bramson and co-workers had early on 
demonstrated that transgene expression after injection of moderate virus doses 
intramuscularly (i.m.) in the thigh were confined to the injection site and the draining lymph 
nodes (Yang et al., 2003).  Recently, they took the mechanistic unraveling an important step 
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further and demonstrated by surgical removal of the nodes that the full response depended 
on intact draining lymph nodes for more than 7 days post infection, but after 20 days they 
were no longer required. These results by themselves could have been an artifact reflecting 
the removal of antigen-specific CD8+ T cells sequestered in the draining lymph nodes rather 
than the abrogation of antigen presentation; yet they are consistent with the conclusions we 
drew from our experiments with L-selectin deficient mice.  However, even in “denoded” 
mice, there was continuous T cell expansion for an additional 3 weeks, which could be 
abrogated by eliminating transcription of the transgene encoding gene using a doxycycline 
repressible system (Finn et al., 2009). This was interpreted by the authors to suggest that i.m. 
inoculation of adenovirus leads to extra nodal, but transgene expression dependent 
prolonged T cell expansion. To address this issue in detail they generated bone-marrow 
chimeric mice in which bone marrow cells from mice lacking the MHC element restricting 
the relevant transgene derived epitope was used for reconstitution of lethally irradiated WT 
mice. Using this system, they could confirm that epitopes restricted by MHC molecules only 
expressed by non-hematopoietic cells were driving late T cell expansion. This result was 
taken as evidence for non-hematopoietic antigen presentation by Bramson and co-workers 
and is referred to as such in the following; however, that this is the case has not been 
formally proven. Antigen could still be presented by professional antigen presenting cells 
which have acquired already peptide loaded MHC class I molecules from the surface of 
tissue resident, non-hematopoietic cells, a phenomenon coined by the phrase “cross-
dressing” (see figure 4C) (Dolan et al., 2006). Nevertheless, the T cells maintained 
exclusively by so-called non-hematopoietic antigen presentation showed marked 
deficiencies in particular with respect to cytokine production, but also featured a more 
pronounced effector memory surface phenotype as compared with T cells generated in 
context of both hematopoietic and non-hematopoietic antigen-presentation. These 
phenotypic differences were roughly identical to those we had previously observed when 
comparing responses elicited by i.v. administration with those elicited by s.c. 
administration. Importantly, the dysfunctional T cells, be they induced by i.v immunization 
or non-hematopoietic priming were quite capable of performing cytotoxic activity. We also 
found i.v. primed T cells to be efficient in protection against vaccinia challenge (Holst et al., 
2010b), whereas Bramson and co-workers found that non-hematopoietic primed T cells were 
partially effective against LCMV or melanoma (Bassett et al., 2011).  Importantly, we also 
found the T cells induced by i.v. administration to be less capable of secondary expansion 
(Holst et al., 2010b), whereas Bramson and co-workers found non-hematopoietic and 
hematopoietic priming equally efficient in inducing memory T cells capable of undergoing 
secondary expansion (Bassett et al., 2011). However, the secondary expansion and 
protection data reported by Bramson and co-workers requires careful evaluation. The 
experiments were performed in vaccinated chimeras with and without hematopoietic 
antigen presentation of the relevant epitopes, and thus the adenovirus induced T cell 
priming as well as the antigen presentation taking place during the challenge phase would 
be affected. This might not be important during melanoma challenge, but certainly would 
impact the effector phase of the responses to infections with rapidly replicating viruses such 
as LCMV, vaccinia virus or influenza. Furthermore, as the capacity for protection was 
evaluated through the challenge of intact animals rather than by adoptive transfers of 
primed donor cells into naïve hosts, we do not know the phenotype of the cells actually 
responding. Importantly, during early primary expansion of OVA specific T cells 
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hematopoietic and non-hematopoietic antigen presentation worked synergistically to 
increase CD8+ T cell numbers, but only hematopoietic antigen presentation supported 
sustained functionality as measured by cytokine competence (Bassett et al., 2011). Notably, 
beyond 20 days post vaccination only extra-nodal expansion contributed to the T cell 
response. This method of antigen presentation is highly important during the early memory 
phase of the response as cessation of antigen expression by a doxycycline regulated vector 
drastically reduced the magnitude of late memory responses (Finn et al., 2009). Our tools 
did not allow detailed control of antigen expression, but we also observed a continuous 
expansion of memory T cells from 20 to 60 days post vaccination following high-dose i.v. 
adenovirus vector administration (Holst et al., 2010b).  
2.3 Model for adenovirus induced CD8+ T cell responses  
Although there are differences between the studies of Bramson and coworkers using 
doxycycline repressible presentation of the ovalbumine derived SIINFEKL epitope and our 
own using adenovirus encoded β-galactosidase, in particular with regard to the kinetics of 
the induced response, the conclusions drawn in these reports are consistent. Taken together, 
these studies allows us to propose a mechanism by which adenoviral vector delivered 
antigen primes an immune response in part by directly transducing the available tissue 
resident dendritic cells and in part by transduction of the local tissue resident, non-
hematopoietic cells. Regarding the antigen produced by cells at the injection site this may 
either be cross-presented via hematopoietic dendritic cells expressing the same MHC 
molecules as the tissue cells, be presented by the novel mechanism of “cross-dressing” 
described in Bassett et al.(Bassett et al., 2011), or be directly presented to the CD8+ T cells in 
situ (see figure 4 for a complete description of the different mechanisms potentially involved 
in the presentation of antigen). Increasing the inoculum leads to the systemic dissemination 
of viral vector and an altered balance between dendritic cell mediated lymph node 
presentation and presentation mediated by non-hematopoietic cells independent of the 
draining lymph nodes (see figure 3 for a description of the interrelation between virus dose 
and site of antigen presentation). This in turn leads to poorer cytokine producing 
competence. The relative importance of hematopoietic and non-hematopoietic antigen 
presentation at doses below ~109 particles is as yet undetermined, but some studies in mice 
and primates as well as humans have demonstrated the relative stability of the response 
within 10- fold variations of the inoculum (Bassett et al., 2011; Bett et al., 2010), and we have 
seen a plateau of the response between ~109 to ~108 particles administered s.c., with a 
gradual reduction of the magnitude of the response upon further dose reductions (Holst PJ, 
Thomsen AR and Christensen JP,unpublished and (Flatz et al., 2010)). A possible 
explanation for these plateaus could be that these doses are sufficient to target all the 
relevant professional antigen presenting cells present at the injection site, and that the major 
difference between the doses are in the degree of non-dendritic cell targeted transduction. 
As the non professional APC transduction leads to poorer cytokine producing competence 
and generation of more terminally differentiated cells, it is worth noticing that we have 
observed an increase in the ratio of CD127high cells compared to KLRG1high cells as the dose 
was further decreased (Holst PJ, Thomsen AR and Christensen JP, unpublished), and that 
termination of transgene expression after the acute response led to higher frequencies of 
central memory T cells, and higher CD27 expression, and a lower frequency of KLRG1 
expression on the responding T cells (Finn et al., 2009).  
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Fig. 3. Relative contribution of antigen presentation from different cell types driving  the  
CD8+ T cell expansion after peripheral administration of adenoviral vaccines. Injection of 
increasing amounts of adenoviral vaccine initially results in a gradual and dose-dependent 
increase in the transduction of professional antigen presenting cells (APC, represented by a 
ruffled cell placed above the line to the left) and tissue resident parenchymal cells 
(represented by an oval cell placed below the line). The peak level of APC transduction is 
reached at a lower dose than is the parenchymal cell transduction and thus the ratio of APC 
to parenchymal cell transduction gradually declines. Increasing the dose further leads to 
spill-over into the systemic circulation causing transduction of central organs, particularly 
the liver (represented by a hepatocyte inserted next to the line at the top right corner). 
The differences between the response patterns observed by us and by Bramson and co-
workers deserve some consideration. Most remarkably, we find i.v. administration of 1010 
particles (~2x108 IFU) of adenovirus to induce a response that becomes detectable in the 
spleen as late as between 30 and 60 days post vaccination whereas lower doses of virus 
given  i.v. fail to induce any detectable response. Subcutaneous immunization induces an 
earlier response at lower doses. Bramson and co-workers on the other hand detect a 
response in the blood and spleen at 10 to 20 days post i.m. immunization with 107-108 pfu of 
adenovirus encoding SIINFEKL fused to luciferase (Bassett et al., 2011; Finn et al., 2009). 
This difference in the kinetics of the response after i.v. as compared to i.m. administration is 
not likely to be due to differences in antigen as Flatz et al.(Flatz et al., 2010) also noted a 
profound attenuation of the response after intravenously administration of 2.5x108 pfu of 
adenovirus encoding the SIINFEKL containing ovalbumin sequence, whereas a potent 
response was observed at lower doses, all measured at 28 days post vaccination. Thus, 
whereas the difference between our report and the one of Flatz et al. (Flatz et al., 2010), who 
observed a strong response to low doses of ovalbumin encoding adenovirus, are likely due 
to the immunological potency of the encoded antigen (ovalbumin being a potent antigen, 
while β-galactosidase is a weak antigen), the differences between Flatz and Bramson must 
relate to the route of administration. In this regard it is interesting that we observed an early, 
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this response seem to be associated with the transduction of liver cells, and it disappears 
before the systemic response can be measured in the spleen. The most likely explanation for 
this phenomenon is that the early transgene-specific T cell response is aborted within the 
liver parenchyma as previously reported for the adenovirus-specific response following i.v. 
immunization (Liu et al., 2001), and that systemic T-cell expansion can only occur after a 
reduction in transgene expression in the liver or when a lower inoculum has been used to 
induce the response as seen by Flatz et al.(Flatz et al., 2010). Based on our findings that 
peripheral virus administration leads to a marked increase in hepatic transduction when the 
dose is increased from 109 to 1010 particles, and that the entire increase in dose at 1011 
particles enters the systemic circulation, we would think that working with peripheral 
administration of adenovirus at doses above 109 particles in murine systems entails a major 
risk for variability in response magnitude, kinetics and quality. The report from Tatsis et 
al.(Tatsis et al., 2007a) can be seen to support this conclusion as i.v. administration of 1010 
adenoviral particles expressing LCMV glycoprotein gave a result midway between our 
results with i.v. administered β-gal at 1010 and s.c. administered β-gal at 1011 particles, 
whereas 1011 particles given  i.m. induced a biphasic response. Hypothetically, the 
elimination of the first phase could be due to intrahepatic sequestration. 
The delineation of adenovirus induced immune responses in hematopoietic and non-
hematopoietic is recent, and the mechanisms of the non-hematopoietic antigen presentation 
is unknown. However, although non-hematopoietic antigen presentation is a novel finding 
for adenovirus induced immunizations, it is not the only system in which it is described. 
Thus, during allogenic bone marrow transplantation, non-hematopoietic antigen 
presentation contributes both to induction of T cells incapable of recall responses and 
functional exhaustion of T cells already generated (Flutter et al., 2010). What is special about 
the adenoviral immunization after a low dose injection is that it is taking place at a defined 
site and should in theory by highly amendable for studying. In any case, more attention 
should now be directed towards the events taking place at the site of adenovirus 
inoculation, because these appear to be crucial for both the immunological potency of 
adenoviral vectors and for excessive differentiation of adenovirus primed CD8+ effector T 
cells.  
For non-hematopoietic antigen presentation to occur one must assume that either a local 
environment capable of causing naïve T cells activation is induced by the interaction of the 
immune system and persisting antigen, or that the antigen is transported to secondary 
lymphoid organs by macrophages or dendritic cells cross-dressed with loaded peptide/MHC 
complexes derived from dying (?) cells within the infected tissue (see figure 4 for an overview 
of potential mechanisms). Potentially, cross-dressing of APCs at the injection site could occur 
either through capture of exosomes by dendritic cells (Utsugi-Kobukai et al., 2003) or through 
a cell-contact dependent mechanism (Dolan et al., 2006), although it should be noted that 
recent studies have questioned the ability of exosomes to contribute to relevant responses 
against viral infections in vivo. However, in the latter case the antigens tested have been 
different and the sensitivity of the assays may have been rather low (Coppieters et al., 2009). 
That expression of foreign antigen following adenoviral vector injection contributes to an 
inflammatory infiltrate seems beyond question as no long term infiltrate can be seen following 
injection with vectors devoid of viral genes and a transgene which does not prime an immune 
response (Chen et al., 1997), yet the interest in such infiltrates have focused on their ability to 
clear gene therapy vectors rather than on their role in supporting immune responses. Thus, at 
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present, we know the infiltrates contain CD4+ and CD8+ T cells, few macrophages but little 
else. In other systems, chronic or extended inflammation has been seen to induce lymphoid 
like structures within parenchymatous  organs such as the CNS, kidneys (Moskophidis et al., 
1987) and bronchi (Moyron-Quiroz et al., 2004), and such changes could possibly also take 
place following adenovirus immunizations. A more thorough understanding of the events 
occurring at the injection site could perhaps lead to strategies impeding excessive T cell 
differentiation without removing antigen stimulation and thus result in generation of even 
more potent vaccines. 
 
 
Fig. 4. Overview of the potential antigen presentation mechanisms after adenoviral 
vaccination. All the cartoons feature an oval tissue resident parenchymal cell in the bottom, a 
ruffled professional antigen presenting cell in the middle and a lymph node with afferent 
lymphatic vessels to the left. CD8+ T cells are drawn with a dark blue nuclei and dark purple 
cytoplasm. MHC class I molecules are yellow, whereas the presented recombinant antigen is 
red. Replication incompetent vectors are hexagonal containing double stranded DNA. A) 
Direct presentation. Professional APCs are directly transduced by the adenoviral vector, 
migrate to the draining lymph nodes and presents antigen synthesized within themselves to 
the CD8+ T cells. B) Cross-presentation. Tissue resident parenchymal cells are transduced and 
professional APCs take up the antigen, process it, migrate to the draining lymph node and on 
their own MHC molecules present the antigen to the CD8+ T cells. C) Cross-dressing. Tissue 
resident cell process and initially presents the antigen. However, somehow MHC/peptide 
complexes are released and taken up by APCs, which migrate to the draining lymph node and 
present the antigen to the CD8+ T cells on MHC molecules synthesized within the 
parenchymal cells. D) Local presentation by APCs. Tissue resident cells are transduced, but 
the antigen remains at the injection site. Resident and inflammatory APCs present antigen to 
CD8+ T cells locally, either from processing of tissue debris or from presentation of MHC 
molecules already loaded with antigen in the parenchymal cells. E) Local presentation 
without APC’s. Tissue resident parenchymal cells are transduced, process the antigen and 
present it to CD8+ T cells locally on their own MHC class I molecules.  
2.4 The issue of quality 
The proposed model has profound implications for interpreting the existing literature and 
in appreciating the potential potency of adenoviral vectors for vaccination use. First of all, it 
partially explains why functionally exhausted T cells are a feature of increasing the dose 
beyond 109 particles (in mice). Secondly, as chronic non-hematopoietic antigen presentation 
A B C D E 
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cannot be avoided, it may also help explain why adenovirus induced CD8+ T cells tend to 
be more terminally differentiated than are T cells induced by live viral vaccines or MVA 
vectors. As murine studies reporting an exhausted phenotype of adenovirus induced CD8+ 
T cells have typically involved virus doses in the range of 1010-1011 viral particles (Tatsis et 
al., 2007a; Yang et al., 2006), one might question the relevance of the results obtained when it 
comes to human or primate vaccination, where the virus dose is typically in the order of 
1010-1011 particles (Bett et al., 2010). In contrast to the studies using high doses of adenoviral 
vectors in mice, CD8+ T cells induced by adenoviral vaccination in primates and humans 
are cytokine competent and cytotoxic cells, but seemingly terminally differentiated effector- 
like cells are found in the circulation for extended periods of time. A key question in this 
respect is whether this should be of significant concern. In the opinion of these authors it 
should not. Under the premise that the adenoviral infection is not overdosed, the phenotype 
of adenovirus primed CD8+ T cells resemble that of T cells found in association with 
chronic, but well-controlled viral infections such as Epstein Barr virus infection in human 
(Ibegbu et al., 2005) and γ herpes virus-68 (MHV-68) infection in mice (Cush & Flano, 2011). 
A key cell surface marker in this context is KLRG1, the expression of which is often taken to 
indicate replicative senescence. However, in EBV infected humans it has been found that 
while KLRG1 is indeed expressed by terminally differentiated T cells, by no means all 
KLRG1high cells are end cells, but rather seem to represent a subset of memory cells 
associated with antigen persistence (Ibegbu et al., 2005). Along the same lines the meticulous 
study by Cush and Flãno (Cush & Flano, 2011) have clearly demonstrated that KLRG1high 
CD8+ T cells in MHV-68 infected mice are fully functional, can expand upon reactivation 
and provide even better protection against reinfection than do KLRG-1low cells with the 
same specificity. Furthermore, despite having predominantly an effector memory 
(CD62LlowCD43low) phenotype, KLRG1high CD8+ T cells may express receptors for 
homeostatic cytokines (IL-7 and IL-15) and can survive long-term in the absence of cognate 
antigen. Thus, although expression of KLRG1 may be associated with a decreasing potential 
for expansion, there are numerous observations indicating that these cells may be protective, 
and by way of their immediate effector capacity in fact could represent the most optimal 
type of vaccine-induced T-cell defence despite some limitations in proliferative capacity 
(Bachmann et al., 2005). An earlier study by the group of Rafi Ahmed investigating the 
responsiveness of mice undergoing repeated antigenic stimulation supports this view 
(Masopust et al., 2006). These authors found that increasing the number of antigenic 
challenges preferentially promoted the generation phenotypically similar memory cells that 
retained effector-like properties and showed preferential accumulation in non-lymphoid 
organs. Notably, neither the adenovirus primed CD8+ T cells nor those driven by repeated 
antigenic stimulation express the inhibitory receptor PD-1 typical of dysfunctional T cells 
(Barber et al., 2006; Bassett et al., 2011; Masopust et al., 2006).  
3. Increasing the potency of adenovirus vectors 
3.1 Improving antigen presentation  
Even though adenovirus vectored vaccines stand among the most potent vaccine platforms 
for induction of CD8 T cell responses, it is apparent that better vaccines are needed still. Be 
that in magnitude of the response, breadth or phenotype of the induced cells. It is clear that 
simply providing more vaccine or administering adenovirus multiple times provide 
minimal benefit compared to low dose immunization, at least with potent antigens, and 
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while awaiting a deeper understanding of non-hematopoietic antigen presentation, the goal 
is to do more with less (vaccine). Our group, and others in close pursuit, therefore set out to 
identify the mechanisms that would be rate limiting for adenovirus induced immune 
responses. We had prior experiences with enhancing the immune responses to DNA 
vaccines by covalently linking an ER exported minimal epitope to β-2 microglobulin as 
described (Uger et al., 1999; Uger & Barber, 1998), thereby presumably increasing the direct 
antigen presentation on DNA transduced cells (Bartholdy et al., 2003; Bartholdy et al., 2004). 
When the same antigen was cloned into an adenoviral vector and compared to full length 
LCMV glycoprotein, we saw an acceleration and augmentation of the response, and the 
transgene specific response which otherwise depended on CD4+ T cell help could now be 
induced in MHC class II deficient mice (Holst et al., 2007). We have since confirmed that the 
transgene works by loading the encoded antigen directly onto the MHC in a processing 
independent manner as TAP deficient cells transduced with adenoviral vectors expressing 
the β-2 microglobulin fused minimal epitope were fully competent in stimulating antigen 
specific T cells in vivo whereas an antigen expression system more potent in WT mice was 
not (Holst PJ and Bassi MR, unpublished).    
3.2 Increasing the breadth of the CD8+ T cell response 
We were surprised to find that the native LCMV glycoprotein induced a CD8+ T cell 
response which were severely limited in breadth and predominantly focused on the 
immunodominant GP33 epitope. In retrospect, the limited breadth of the induced response 
is perhaps not so surprising and tends to be a general draw-back of viral vectored vaccines. 
The vector backbone of adenoviruses, poxviruses and other systems encode many T cell 
epitopes which may compete with the transgene for the attention of the CD8+ T cells 
(Schirmbeck et al., 2008). In a search for adenovirus vaccine modifications which might lead 
to broader T cell responses, we decided to improve MHC class II restricted antigen 
presentation by covalently linking the encoded antigen to the MHC class II associated 
Invariant chain (Diebold et al., 2001; Holst et al., 2008; Rowe et al., 2006). Surprisingly, this 
strategy improved not only CD4+ T cell responses, but also the kinetics, breadth, magnitude 
and stability of the CD8+ T cell response via increased MHC class I presentation and 
independently of MHC class II (Holst et al., 2011). We have since then confirmed these 
findings with a variety of antigens and are able to conclude that the level of antigen 
presentation on the adenovirus transduced cell is a limiting factor with regard to the speed 
and breadth of CD8+ T cell responses (Hoegh-Petersen et al., 2009; Mikkelsen et al., 2011; 
Sorensen et al., 2009). Given the apparent dichotomy of fast hematopoietic and chronic non-
hematopoietic antigen presentation in adenoviral vaccination, this is highly consistent with 
the hypothesis that the above described strategies work at least in part to increase the first 
wave of antigen presentation mediated by dendritic cells directly transduced by the vector 
(see figure 2). Remarkably, the CD8+ T cell response induced by adenoviral vaccination 
with this type of modified construct seem to have acquired a normal contraction phase and 
the CD8+ T cell response typically stabilizes at approximately 10% of the level of the peak 
response (see figure 1). Though augmentation of direct early presentation should lead to an 
accelerated response, it is unclear if this would also result in reduced late phase presentation 
thereby allowing the return to a nearly normal contraction pattern. One could speculate that 
increased MHC class I restricted antigen presentation, also in the tissue resident cells, would 
result in more efficient antigen elimination at these sites by the antigen-specific CD8+ T 
cells, but it is also possible that CD4+ T cells and MHC class II restricted antigen 
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presentation by tissue resident cells could play a role. Thus, the more efficient early 
induction of CD4+ T cells by the MHC class II associated Invariant chain linked constructs 
combined with local production of interferon-γ,  which could cause local MHC class II up-
regulation and antigen presentation, might together set the stage for CD4+ T cell mediated 
antigen elimination.  
3.3 Role of CD4+ T cell help 
Interestingly, we also found that while ordinary adenovaccine primed CD8+ T cell 
responses were CD4+ T-cell help dependent, neither of the tethered constructs required 
CD4+ T cells for induction of a primary CD8+ T-cell response (Holst et al., 2007; Holst et al., 
2011). However, as has previously been observed also with fully CD4+ T-cell helped CD8+ T 
cells, the functionality of the generated cells decreased faster in a CD4+ T-cell deficient 
environment  (Sun et al., 2004). Still, however, we saw significant protection against a high-
dose viral challenge in MHC class II deficient mice at 2 months post vaccination, which 
matched that found in wild type mice vaccinated with an ordinary adenovirus vaccine 
(Holst et al., 2007; Holst et al., 2011). This ability of our improved vaccine to induce an 
efficient acute and prolonged CD8+ T cell response in the absence of CD4+ T cells have clear 
implications as regards certain states of clinical immunodeficiency. Thus, in bone-marrow 
transplant recipients herpes virus infections represent a serious clinical problem. However, 
as the CD8+ T-cell population in these patients recovers faster than the CD4+ T cell 
population (Berger et al., 2008), this type of vaccine could be used to curtail such infections 
until the CD4+ T-cell population is restored.   
Although several strategies can increase the immune response resulting from DNA 
vaccination there are not many strategies that have been published to augment the response 
to adenovirus vectored vaccines (reviewed in Holst et al. 2010 (Holst et al., 2010a)). Whether 
this reflects that very few strategies have actually been tested or that they have not worked 
efficiently is a matter of speculation, but it is tempting to conclude that virus vectored 
vaccines contains sufficient pathogen- associated molecular patterns to substitute for many a 
cytokine co-administered with the vaccine. Exceptions to the general rule has been antigen 
linked to the herpes viral tegument protein VP22 and calreticulin, which have been tested in 
Sindbis virus replicon particles (Cheng et al., 2002) and vaccinia vectors (Hsieh et al., 2004), 
respectively, and the herpes viral glycoprotein D (gD), which has been tested using an 
adenoviral vector. Both VP22 and calreticulin are suggested to work by increasing antigen 
presentations, but the herpes viral glycoprotein D was postulated to work by competitive 
inhibition of the interaction between the herpes virus entry mediator (HVEM) and the B and 
T lymphocyte attenuator (BTLA) (Lasaro et al., 2008). Although herpes viral gD fused to 
antigen was convincingly showed to interact with HVEM, there were no experiments 
performed in animals or cells deficient in HVEM or BTLA, nor was antigen presentation 
measured following use of this strategy. Thus whether or not HVEM-BTLA interaction is 
important in the immune response to adenoviral vectors remains to be determined (see 
(Holst et al., 2010a) for a detailed comment on this study). The MHC class II associated 
invariant chain linked antigen concept was also tested as a DNA vaccine, and found to 
increase CD8+ T cell responses working both alone and as a primer for an adenoviral boost. 
Moreover, the MHC class II associated Invariant chain linked antigen concept was also 
beneficial when applied in the booster supporting the conclusion that increased direct 
presentation benefits adenovirus induced CD8+ T cell responses after the initial priming 
(Grujic et al., 2009).  
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4. Adenovirus vectored vaccines compared to other vaccine technologies 
4.1 Adenovirus induces unusually potent and protective CD8+ T cell responses 
With regard to sheer potency of long term CD8+ T cell induction there are only a few 
reports challenging the supremacy of adenovirus vectors, and none of these have been 
verified in humans. In primates, adenoviral vectors have been tested side-by-side with MVA 
and DNA vectors and matched studies have been performed in humans (Bett et al., 2010; 
Casimiro et al., 2003; Shiver et al., 2002). These studies have unequivocally shown that 
adenoviral vectors induce superior frequencies of CD8+ T cells and, importantly, induce 
better T cell mediated protection against simian human immunodeficiency virus challenge 
(SHIV) in NHP’s. However, other general findings include a low proliferative potential of 
induced T cells, effector memory rather than central memory phenotype of the induced T 
cells and a low frequency of IL-2 producing T cells (Tatsis et al., 2007a; Yang et al., 2006; 
Yang et al., 2007). Although several studies have addressed potency and immunogenicity of 
antigen presentation from various vectors, few direct comparisons exists between 
adenoviral vectors and other popular virus vectored vaccine candidates, most notably MVA 
and fowlpox vectors. A recent study has been made in mice comparing human adenovirus 
serotype 5, simian serotype C6, fowlpox vectors and MVA. These studies confirmed the 
tendencies reported above, but remarkably again demonstrated a superior protective 
efficacy of the adenoviral vector system. Thus, even though adenovirus vectors induce 
CD8+ T cells with functional and phenotypic properties most similar to those found in 
association with unresolved chronic infections, they still stand as superior vectors for T cell 
mediated protection against acute and chronic infections (Shiver et al., 2002; Sridhar et al., 
2008). A paradox which has caused confusion, but in the opinion of these authors, a paradox 
which can be easily be appreciated if one considers the impact of the acute phase of an 
infection as a major determinant of the course of the chronic phase of an infection. Also, the 
negative result of the STEP trial regarding clinical protection against HIV may have 
attracted much too negative attention to the adenoviral vector system. Recent follow- up 
data of infected vaccinees revealed that the infecting HIV strains have accumulated 
mutations matching the most immunogenic epitopes of the vaccine, thus demonstrating that 
the adenovirus vectored vaccine has exerted an efficient selection pressure upon the 
infecting virus (Rolland et al., 2011). In conclusion, the vaccine induced T cells did work, but 
as the vaccine induced T-cell responses were rather narrowly targeted  and raised against T-
cell epitopes that can readily be mutated, the induced response simply was not sufficient to 
permanently control infection with a rapidly mutating virus like HIV. Some improvement 
strategies to the immunogenicity of the adenovirus vaccines have been discussed above (see 
the “Increasing the potency of adenovirus vectors” section above), whereas the most 
commonly applied strategy, prime-boost regimens will be discussed below. 
4.2 Adenovirus induced antibody responses 
Although the major focus of this review is on adenovirus induced T cell responses, it should 
be noted that the benefits of adenoviral vectors for induction of antibody responses is less 
clear. It is noteworthy that adenoviral vectors, despite their capacity for induction of high 
titers of antibodies, may fall short of MVA vectors when it comes to induction of cross-
reacting antibodies against influenza and SIV. Thus, MVA vectors expressing the 
hemagglutinin antigen of influenza A H5N1/Vietnam/2004 provide efficient cross-clade 
protection against H5N1/Indonesia/2005 challenge in primates (Kreijtz et al., 2009), 
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whereas similar adenovirus vectors appear less potent, and infectious virus may still be 
detectable after homologous challenge (Gao et al., 2006). Direct comparisons are lacking. 
Similarly, in the SHIV system, Robinson and colleagues have developed a DNA and MVA 
based vaccine which uses the large cloning capacity of the poxvirus vector to 
simultaneously encode gp41 and gag and thus produce virus-like particles. Highly avid 
antibodies to native gp41 appear to constitute a correlate of protection against peak viremia 
which transcends into improved control in the chronic phase of the infection (Zhao et al., 
2009). Again, a similar strategy has not been tested with adenovirus vectors. Thus, there is 
suggestive evidence that MVA vectors are superior or at least as potent as adenovirus 
vectors with respect to induction of broadly reactive antibodies. Why adenovirus vectors 
induce superior CD8+ T cell responses, but only comparable antibody responses has not 
been systematically addressed. However, as vectors such as the MVA induce their 
associated immune response in considerable less time than do the adenoviral vectors, the 
former could be speculated to rely on the recruitment of more B cell precursors to reach the 
same levels as the adenovirus vectored vaccines and therefore induce more diverse 
responses. 
5. Use of adenovirus vaccines in prime-boost regimens 
5.1 Use of adenovirus in heterologous prime-boost regimens 
Pre-clinically, adenovirus vectors have been used rather successful as boosters for DNA 
immunizations, and paradoxically as they potentially induce memory T cells with a 
restricted proliferative potential, also as primers for poxvirus booster immunizations. The 
use of DNA priming is logical and results in a broadening of the CD4+ T cell response, an 
increase in the IL-2 competence of the primed CD8+ T cells and improved protection after 
SIV challenge (Casimiro et al., 2005; Cox et al., 2008; Wu et al., 2005). Please note that 
although some animal studies point to an improved immunogenicity of DNA primed 
adenovirus immunizations (Grujic et al., 2009), this has not been verified in humans (Bett et 
al., 2010). Although DNA primed adenovirus immunization have shown some promise, it 
pales in comparison to the recent pre-clinical results obtained using adenoviruses of 
different serotypes (Liu et al., 2009) or adenovirus as primers for MVA vectors (Reyes-
Sandoval et al., 2010). The use of such prime-boost regimens have improved the protective 
efficacy against SIV or rodent malaria compared to the use of either vector system alone, 
although it should be stressed that the reason for the improved protection is unclear. The 
heterologous adenovirus based immunization by Barouch and co-workers induced 
increased CD4+ T cell responses and CD8+ T cells of increased functionality, but the 
correlate of protection was with the breadth of the response (Liu et al., 2009). Similar 
phenotypic changes were seen in a rodent malaria model, yet here protection was correlated 
with the total numbers of IFN-γ producing CD8+ T cells (Reyes-Sandoval et al., 2010). As 
noted above, all these data strongly suggest that the T cells induced by adenoviral 
immunization are at least acutely protective. Notably, by documenting the ability of 
adenoviral vectors to prime for subsequent responses, these observations also questions the 
notion that adenovirus induced T cells necessarily have a limited proliferative capacity. Not 
only vaccines can boost adenovirus primed responses, also live LCMV infection in mice 
(Holst et al., 2011) or SIV in primates (Liu et al., 2009; Sun et al., 2008) cause massive post-
exposure expansion of adenovirus primed T cells. In this context it is noteworthy that direct 
analysis of the adenovirus primed T cells’ ability to proliferate have mostly been performed 
www.intechopen.com
 Harnessing the Potential of Adenovirus Vectored Vaccines 183 
following what seems likely to be represent inoculation of unreasonably high doses of virus 
(see above for details), and the obtained results may therefore not be very relevant to a more 
real-life vaccine situation. An additional factor explaining the discrepancy may be that ex 
vivo analysis of proliferative capacity is typically performed on either blood or spleen cells, 
whereas an infection or an immunization can boost any T cell population present in the 
challenged animal. The phenotype and tissue localization of T cells responding with 
proliferation in response to a secondary immunization or challenge infection remains 
unknown, and the most relevant cells may not be present in blood or spleen in significant 
quantities. 
5.2 Heterologous prime-boost regimens impact T cell quality 
The study of Barouch and co-workers revealed an impact of the particular adenoviral 
serotype used for priming, on the phenotype and functionality of the ensuing T cell 
response, and suggested that special rare serotypes may have unique properties (Liu et al., 
2008). However, as noted above, the heterologous prime-boost regimens in rodents using 
malaria antigens also reported an increased functionality of the induced CD8+ T cells 
(Reyes-Sandoval et al., 2010). An interesting observation in this regard was made when a 
triple sequential immunization was attempted using two different serotype of adenoviral 
vectors together with MVA. The third immunization induced further expansion of the CD8+ 
T cell response, increased their tissue homing and increased their cytokine producing 
competence (Tatsis et al., 2007b). Whereas expansion and increases in tissue homing 
capacity may be general phenomena following sequential immunization and has been seen 
in other systems as well as (Masopust et al., 2006), the increase in cytokine producing 
competence following the third immunization is harder to explain and has not been 
investigated. However, it is possible that the very strong response of transgene specific 
tissue homing CD8+ T cell may contribute to a rapid reduction of tissue localized vector, 
which would be in line with the notion that this pool of antigen contributes to induce CD8+ 
T cells of low cytokine producing competence. 
6. Disease indications where the attributes of adenoviral vectored vaccines 
are especially useful 
In principle adenoviral vectors would be useful wherever a strong and sustained antibody 
and/or CD8+ T cell response is readily inducible and contributing to protection. Acute 
infections such as avian influenza (Gao et al., 2006), Ebola (Richardson et al., 2009; Sullivan 
et al., 2003), foot-and-mouth disease virus (Pacheco et al., 2005) and rabies (Hu et al., 2006) 
are prime examples , but the list of published pre-clinical infections with high efficacy of 
adenovirus based vaccines essentially goes on and on. However, the more challenging 
vaccine targets are undoubtedly those involving infections with a propensity to become 
chronic such as HIV, HCV and the herpesviruses, or those where antibody inducing 
immunization may potentially exacerbate disease, such as dengue virus. These viruses have 
in common that sufficiently broad, high-titered and stable antibodies cannot readily be 
induced and that T cells therefore are needed to do the job. Accordingly, fairly solid pre-
clinical data using adenoviral vectors have been obtained in the SIV model system (Liu et 
al., 2009) and the chimpanzee model of HCV infection (Folgori et al., 2006). However, the 
scientific community is still debating how to improve this further and develop clinically 
useful vaccines. In this review we would offer a different opinion from that of the majority 
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regarding such diseases. Thus, while the focus have been on inducing immune responses 
capable of persisting during chronic infections, it is worth remembering that no actual 
intervention strategy succeeding in contributing to chronic virus control have done so 
without first reducing acute viral replication. An interesting case in this context is the SIV 
model for HIV infection. In this system, rapid application of highly active anti-retroviral 
therapy can lead to complete control of the virus and even protection against rechallenge 
(Lifson et al., 2001). This suggests that the rapidity of early virus control should be the goal 
for vaccine development. Another case supporting this suggestion is found in the MHV-68 
model. In this system, a potent adenovirus vectored vaccine capable of reducing the splenic 
viral load after 14 days, was unable to impact the level of the latent infection. However, local 
immunization using intranasal application of the vaccine resulted in enhanced acute control 
at 7 days after infection as well as in improved control of the latent infection (Hoegh-
Petersen et al., 2009). The lesson for vaccine development seems to be that increased efficacy 
can be expected against different disease targets by ensuring that CD8+ T cells are present 
and efficient at the site of virus entry/early virus replication and, furthermore, that these 
cells can rapidly acquire effector functions and reduce the viral load. Regarding the 
phenotype associated with acute control, adenovirus vaccines induce CD8+ T cells that for 
extended periods of time can exert immediate cytotoxic activity whereas immediate effector 
functions are quite limited in the less differentiated central memory T cells that seem to 
accumulate during controlled SIV or HIV infection. Also, regarding the ability to apply 
vaccines in manners that will induce local immunosurveillance at the likely site of virus 
entry or early replication, adenoviral vaccines have been found to be very useful. Thus, 
studies have suggested that local application can be used to augment mucosal CD8+ T cell 
memory (Belyakov et al., 2008; de Souza et al., 2007; Kaufman et al., 2010; Lemiale et al., 
2007), and also that parenteral immunization can be used to induce T cell homing to 
mucosal sites (Haut et al., 2010; Kaufman et al., 2010; Lin et al., 2007; Tatsis et al., 2007b). The 
ability to induce local T cell responses is not a quality unique to adenovirus vectors and 
local immunity can also be obtained by mucosal application of pox-viral vectors (Corbett et 
al., 2008). Unfortunately, direct comparisons of vector systems for induction of mucosal 
immune responses seem to be lacking. While it may seem encouraging that parenteral 
immunization induces efficient T cell memory at mucosal sites, it should be noted that the 
assays performed to document mucosal homing are typically performed using tissue 
fractions or whole tissue homogenates. When we attempted a clean sampling of CD8+ T 
cells patrolling the mucosal surface of the lungs and airways by harvesting the 
bronchioalveolar lavage (BAL), only minimal frequencies of antigen specific cells could be 
detected after s.c. immunization whereas robust responses were seen after a single 
intranasal immunization. It seems possibly that there may be a difference between inducing 
the migration of T cells into a tissue with a large mucosal surface and to actually make the 
cells dedicated with respect to patrolling this surface for infected cells. In support of a 
compartmentalized CD8+ T cell memory at mucosal organs, immune responses in the 
mesenteric lymph nodes,  which are frequently interpreted as a sign of induction of mucosal 
immunity in the gut, are efficiently induced following i.m. adenoviral immunization 
(Kaufman et al., 2010; Lin et al., 2007), whereas genuine mucosal immunization does not 
increase T cell frequencies in this site (Belyakov et al., 2008). Fortunately, concomitant 
subcutaneous and intranasal administration can induce T cell memory at both mucosal 
(BAL) (Hoegh-Petersen et al., 2009) and systemic (spleen) sites  (these authors and Mette 
Hoegh-Petersen, unpublished). 
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7. Future perspectives 
Apart from attempting to combat chronic infections prophylactically, the realization that 
adenovirus primes T cells for extended periods of time based on extra-nodal and perhaps 
even non-hematopoietic antigen presentation opens up an interesting avenue for further 
studies. Thus, as the understanding of extranodal priming increases, so will the ability to 
modulate it, for instance by co-encoding cytokines or inhibitors of immunomodulatory 
molecules. Adenovirus vectors could in this respect have unique qualities which could be 
exploited for therapeutic vaccines against cancer or chronic infection.    
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